CD8+ T-cell responses against oncogenic papillomaviruses - Are they useful?

Papillomavirus Report

Volumn 16, Issue 1, 2005, Pages 1-7

  Man, Stephen ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CIDOFOVIR; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMIQUIMOD; PROTEIN E6; PROTEIN E7; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE; WART VIRUS VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CARCINOGENICITY; CELL CULTURE; CELL DEATH; CELL INFILTRATION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA; CROSS REACTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DNA METHYLATION; DOWN REGULATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; EXOCYTOSIS; FLUORESCENCE ACTIVATED CELL SORTER; GENETIC HETEROGENEITY; GENOME ANALYSIS; HEPATITIS B; HLA MATCHING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INNATE IMMUNITY; MASS SPECTROMETRY; MONOTHERAPY; NONHUMAN; PAPILLOMA VIRUS; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA; VIRUS GENOME; WART VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 16344392527     PISSN: 09574190     EISSN: None     Source Type: Journal    
DOI: 10.1179/095741905X24987     Document Type: Review

References (85)

1. + T cells. Curr Opin Immunol 1998;10:444-9.
2. Welters MJ, de Jong A, van den Feden SJ, van der Hulst JM, Kwappenberg KM, Hassane S et al. Frequent display of human papillomavirus type 16 E6-specific memory T-belper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003;63:636-41.
3. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64:5449-55.
4. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9.
5. Hohn H, Pilch H, Gunzel S, Neukirch C, Freitag K, Necker A et al. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. J Virol 2000;74:6632-36.
6. + tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 1999;163:5715-22.
7. Warrino DE, Olson WC, Knapp WT, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS et al. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res 2004;10:3301-8.
8. Campo MS. Animal models of papillomavirus pathogenesis. Virus Res 2002;89:249.
9. Moore R. Canine papillomavirus - a mucosal model of human disease. Papillomavirus Reports 2004;15:55.
10. Harwood C, Proby C. Human papillomavirus and immunosuppression. In: Sterling J, Tyring S. (eds) Human Papillomaviruses - Clinical and Scientific Advances. London: Hodder and Stoughton, 2001; 102-17.
11. Bourgault Villada I, Moyal Barracco M, Ziol M, Chaboissier A, Barget N, Berville S et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res 2004;64:8761-6.
12. Stanley MA. Immunobiology of papillomavirus infections. J Reprod Immunol 2001;52:45-59.
13. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000;356 1985-6.
14. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997;57:2943-50.
15. Hong K, Greer CE, Ketter N, VanNest G, Paliard X. Isolation and characterization of human papillomavirus type 6 specific T cells infiltrating genital warts. J Virol 1997;71:6427-52.
16. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-28.
17. Konya J, Eklund C, afGeijersstam V, Yuan F, Stuber G, Dillner J. Identification of a cytotoxic T lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol 1997;78 2615-20.
18. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002;2:401-9.
19. Kägi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369 31-7.
20. Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999;163:4462-72.
21. + T cells. J Immunol 2004; 173:721-5.
22. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000;164:3645-51.
23. Lichterfeld M, Yu XG, Waring MT, Mui SK, Johnston MN, Cohen D et al. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood 2004;104:487-94.
24. Valitutti S, Muller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996;183:1917-21.
25. Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-Joosten AM et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
26. Khammanivong V, Liu XS, Liu WJ, Rodda SJ, Leggatt GR, Tindle RW et al. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16. Immunol Cell Biol 2003;81:1-7.
27. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002;2:59-65.
28. de Jong A, van der Hulst JM, Kenter GG, Drijfhout JW, Franken KL, Vermeij P et al. Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 2005;114:274-82.
29. Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Int Immunol 2005;17:167-76.
30. van der Burg S, Ressing M, Kwappenberg K, de Jong A, Straathof K, de Jong J et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16 ositive cervical lesions: identification of three human leukocyte antigen class II restricted epitopes. Int J Cancer 2001;91:612-3.
31. Youde SJ, Dunbar PR, Evans EM, Fiander AN, Borysiewicz LK, Cerundolo V et al. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte- recognizing endogenous human papillomavirus antigens. Cancer Res 2000;60:365-71.
32. + T cell responses in women with high grade vulvar intraepithelial neoplasia. Int J Cancer 2004;108:857-62.
33. Ressing ME, Sette A, Brandt RMP, Ruppert J, Wentworth PA, Hartman M et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201 binding peptides. J Immunol 1995;154:5934-43.
34. Marsh S, Parham P, Barber L. The HLA Facts Book. London: Academic Press, 2000.
35. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 2000;30:2281-9.
36. Oerke S, Hohn H, Zehbe I, Pilch H, Schicketanz KH, Hitzler WE et al. Naturally processed and HLA-138-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. Int J Cancer 2005;114:766-78.
37. Nakagawa M, Kim KH, Moscicki AB. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol 2004;11:889-96.
38. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264 716-9.
39. Crotzer VL, Christian RE, Brooks JM, Shabanowitz J, Settlage RE, Marto JA et al. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol 2000; 164 6120-9.
40. Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. Curr Opin Immunol 1998;10:478-82.
41. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348 518-27.
42. Rudolf MP, Man S, Melief CJ, Sette A, Kast WM. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin Cancer Res 2001; 7:788s-95s.
43. Williams OM, Hart KW, Wang EC, Gelder CM. Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J Virol 2002;76:7418-29.
44. Youde SJ, McCarthy CM, Thomas KJ, Smith KL, Man S. Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line. Int J Cancer 2005;114:606-12.
45. + T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. J Virol 2003; 77:5464-74.
46. Zhou J, Liu WJ, Peng SW, Sun XY, Frazer I. Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol 1999;73:4972-82.
47. Van Tine BA, Kappes JC, Banerjee NS, Knops J, Lai L, Steenbergen RD et al. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. J Virol 2004; 78 11172-86.
48. Schreurs MW, Scholten KB, Keuter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E. In vitro generation and life-span extension of human papillomavirus type 16 sopecific, healthy donor-derived CTL clones. J Immunol 2003;171:2912-9.
49. Brady CS, Bartholomew JS, Burt DJ, Duggan-Keen MF, Glenville S, Telford N et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 2000;55:401-11.
50. Fowler NL, Frazer IH. Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol 2004;92:914-21.
51. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994;179:335-40.
52. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U et al. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001;167:5420-8.
53. + T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol 2003; 77:2757-61.
54. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause trequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Expl Med 2000;191:961-76.
55. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol 2005;174:41-50.
56. Aguilar-Lemarroy A, Kirchhoff S, Whitaker N, Gariglio P, zur Hansen H, Krammer PH et al. Differential sensitivity of human papillomavirus type 16(+) and type 18(+) cervical carcinoma cells to CD95-mediated apoptosis. Int J Cancer 2001;93:823-31.
57. Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 2001;98:11515-20.
58. Barber DL, Wherry EJ, Ahmed R. Rapid in vivo killing by memory CD8 T cells. J Immunol 2003;171:27-31.
59. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000;103:491-500.
60. Routes JM, Morris K, Ellison MC, Ryan S. Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms. J Virol 2005;79:116-23.
61. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
62. + cells involves a noncytotoxic mechanism. J Virol 1991; 65:5921-7.
63. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46-54.
64. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and type 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7.
65. Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 2004;10:2954-6.
66. Frazer IH, Quinn M, Nicklin JL, Tan J, Perrin LC, Ng P et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004;23:172-81.
67. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6 3406-16.
68. Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003;63:6032-41.
69. Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 2004; 22 2722-9.
70. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002;8:3676-85.
71. Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J et al. Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003;9:5205-13.
72. Smith K, Tristram A, Gallagher K, Fiander A, Man S. Epitope specificity and longevity of vaccine induced human T cell responses against HPV 18. Int Immunol 2005;17:167-76.
73. Cailan ME, Tan L, Annels N, Ogg GS, Wilson JD, O'Callaghan CA et al. Direct visualization of antigen-specific CD8(+) T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-402.
74. van der Burg S. Immunology - Prophylactic vaccination. Papillomavirus Reports 2004;15:168-70.
75. Stanley M. Genital human papillomavirus infections - current and prospective therapies. J Natl Cancer Inst Monograph 117 2003; Chapter 17, 117-24.
76. Christensen ND, Han R, Cladel NM, Picket MD. Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences. Antimicrob Agents Chemother 2001;45:1201-9.
77. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63:8408-13.
78. Small LA, Da Silva DM, de Visser KE, Velders MP, Fisher SG, Potkul RK et al. A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy. Clin Cancer Res 2001;7:876s-81s.
79. Scholten KB, Schreurs MW, Ruizendaal JJ, Kueter EW, Kramer D, Veenbergen S et al. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer. Clin Immunol 2005;114:119-29.
80. Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, Safrit JT et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogervic caspase substrates. Nat Med 2002;8:185-9.
81. Beverley PC, Sadovnikova E, Zhu X, Hickling J, Gao L, Chain B et al. Strategies for studying mouse and human immune responses to human papillomavirus type 16. Ciba Found Symp 1994; 187:78-86.
82. Rosenberg SA, Yang JC, Restifa NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
83. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
84. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Cowan C, Korourian S et al. Development, characterisation and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18-E7 pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix. Eur J Gynaecol Oncol 2000;21:17-23.
85. Matsumoto K, Leggatt GR, Zhong J, Liu X, de Kluyver RL, Peters T et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst 2004;96:1611-9.